SG11201508681QA - Compositions and methods for growth factor modulation - Google Patents

Compositions and methods for growth factor modulation

Info

Publication number
SG11201508681QA
SG11201508681QA SG11201508681QA SG11201508681QA SG11201508681QA SG 11201508681Q A SG11201508681Q A SG 11201508681QA SG 11201508681Q A SG11201508681Q A SG 11201508681QA SG 11201508681Q A SG11201508681Q A SG 11201508681QA SG 11201508681Q A SG11201508681Q A SG 11201508681QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
growth factor
factor modulation
modulation
Prior art date
Application number
SG11201508681QA
Inventor
Thomas Schurpf
Nagesh K Mahanthappa
Michelle Marie Straub
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201508681Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of SG11201508681QA publication Critical patent/SG11201508681QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
SG11201508681QA 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation SG11201508681QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361819840P 2013-05-06 2013-05-06
US201361823552P 2013-05-15 2013-05-15
US201361900438P 2013-11-06 2013-11-06
PCT/US2014/036933 WO2014182676A2 (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation

Publications (1)

Publication Number Publication Date
SG11201508681QA true SG11201508681QA (en) 2015-11-27

Family

ID=51867850

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201800800YA SG10201800800YA (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation
SG10201913751RA SG10201913751RA (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation
SG11201508681QA SG11201508681QA (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201800800YA SG10201800800YA (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation
SG10201913751RA SG10201913751RA (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation

Country Status (18)

Country Link
US (12) US9758576B2 (en)
EP (2) EP3816625A1 (en)
JP (5) JP2016521283A (en)
AU (4) AU2014262843B2 (en)
CA (1) CA2911514A1 (en)
CY (1) CY1123907T1 (en)
DK (1) DK2981822T3 (en)
ES (1) ES2837042T3 (en)
HR (1) HRP20201914T1 (en)
HU (1) HUE052232T2 (en)
IL (3) IL301607A (en)
LT (1) LT2981822T (en)
PL (1) PL2981822T4 (en)
PT (1) PT2981822T (en)
RS (1) RS61778B1 (en)
SG (3) SG10201800800YA (en)
SI (1) SI2981822T1 (en)
WO (1) WO2014182676A2 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080064155A (en) 2005-10-14 2008-07-08 어플라이드 리써치 어쏘시에이츠 뉴질랜드 리미티드 A method of monitoring a surface feature and apparatus therefor
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
CN102056946A (en) 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102568454B1 (en) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9179844B2 (en) 2011-11-28 2015-11-10 Aranz Healthcare Limited Handheld skin measuring or monitoring device
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
TW202340236A (en) 2012-08-24 2023-10-16 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015138385A1 (en) * 2014-03-10 2015-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiologically identifed tumor habitats
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
KR20170066515A (en) * 2014-09-30 2017-06-14 우니베르지타이트 겐트 A method of treating joint disease
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
AU2015342936B2 (en) 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
MX2017008978A (en) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
SG10201910999TA (en) * 2015-05-15 2020-01-30 Agency Science Tech & Res Native protein purification technology
US20180208648A1 (en) * 2015-07-22 2018-07-26 Scholar Rock, Inc. Gdf11 binding proteins and uses thereof
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
EP3350220B1 (en) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
PL3349776T3 (en) * 2015-09-17 2021-08-02 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
HUE057153T2 (en) * 2015-09-17 2022-04-28 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
AU2016361461B2 (en) * 2015-11-26 2020-10-22 Hudson Institute of Medical Research Inhibin analogs
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3400240A2 (en) * 2016-01-08 2018-11-14 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
BR112018068340A2 (en) 2016-03-11 2019-01-15 Scholar Rock Inc tgfss1-binding immunoglobulins and uses of these
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
US10013527B2 (en) 2016-05-02 2018-07-03 Aranz Healthcare Limited Automatically assessing an anatomical surface feature and securely managing information related to the same
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
WO2017218592A1 (en) 2016-06-13 2017-12-21 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
MA45690A (en) * 2016-07-14 2019-05-22 Scholar Rock Inc ANTI-TGFB ANTIBODIES, METHODS AND USES
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
EA201990317A1 (en) 2016-08-16 2019-07-31 Ридженерон Фармасьютикалз, Инк. METHODS FOR DETERMINING THE NUMBER OF INDIVIDUAL ANTIBODIES FROM THE MIXTURE
US20200331984A1 (en) * 2016-09-20 2020-10-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface
CN110494543A (en) 2016-10-19 2019-11-22 弗洛设计声能学公司 Pass through the affine cell extraction of acoustics
ES2924060T3 (en) 2016-10-25 2022-10-04 Regeneron Pharma Procedures and system for analysis of chromatography data
US11136383B2 (en) 2016-10-26 2021-10-05 The Children's Medical Center Corporation Methods and compositions for modulaton of transforming growth factor beta-regulated functions
JP7139326B2 (en) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド ACTIVIN TYPE IIa RECEPTOR MUTANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME MUTANTS
US11116407B2 (en) 2016-11-17 2021-09-14 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
MA47163A (en) * 2016-12-16 2019-11-06 Biogen Ma Inc PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
DK3366306T3 (en) * 2016-12-23 2022-01-10 Univ Istanbul Rektoerluegue Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto
CN117398457A (en) * 2017-01-06 2024-01-16 供石公司 Subtype-specific, background-permissive tgfβ1 inhibitors and uses thereof
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
ES2944357T3 (en) 2017-01-06 2023-06-20 Scholar Rock Inc Treatment of metabolic diseases by inhibiting myostatin activation
TWI788321B (en) 2017-01-20 2023-01-01 美商健臻公司 Bone-targeting antibodies
US10900786B2 (en) 2017-03-31 2021-01-26 International Business Machines Corporation Refining an ecological niche model
US11903723B2 (en) 2017-04-04 2024-02-20 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
FI3621694T3 (en) 2017-05-09 2023-08-28 Scholar Rock Inc Lrrc33 inhibitors and use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US20210087240A1 (en) * 2017-07-19 2021-03-25 Musc Foundation For Research Development Blocking garp cleavage and methods of use thereof
WO2019021229A1 (en) * 2017-07-26 2019-01-31 Ftf Pharma Private Limited Liquid dosage forms of imatinib
WO2019023661A1 (en) * 2017-07-28 2019-01-31 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2021507561A (en) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． Acoustic Transducer Driver and Controller
JP2021518745A (en) 2018-01-12 2021-08-05 ケロス セラピューティクス インコーポレイテッドＫｅｒｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Activin type IIB receptor mutants and how to use them
AU2019231307A1 (en) * 2018-03-09 2020-10-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
TW202005694A (en) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
CA3105988A1 (en) * 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
EP3677278B1 (en) 2018-07-11 2021-11-10 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CA3128042A1 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf.beta. and uses thereof
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
JP7350242B2 (en) * 2019-07-19 2023-09-26 国立研究開発法人理化学研究所 Antibody against LAP fragment of human TGF-β and its use
TWI737469B (en) 2019-08-28 2021-08-21 日商中外製藥股份有限公司 Cross-species anti-latent tgf-beta 1 antibodies and methods of use
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
US20220372135A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CN111072764A (en) * 2019-12-13 2020-04-28 东莞市东阳光生物药研发有限公司 Preparation method of recombinant human Activin A
JP2023511255A (en) 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド TGF-β inhibitor and use thereof
MX2022008609A (en) 2020-01-11 2022-11-10 Scholar Rock Inc Tgfî² inhibitors and use thereof.
CN115243724A (en) 2020-02-19 2022-10-25 纳米医疗有限公司 Formulated and/or co-formulated liposomal compositions containing TFG beta antagonist prodrugs and methods thereof useful for treating cancer
EP4121090A1 (en) * 2020-03-20 2023-01-25 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A1 (en) * 2020-03-20 2023-01-25 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
AU2022299185A1 (en) 2021-06-23 2024-01-25 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
GB202203269D0 (en) * 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5001225A (en) 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (en) 1988-09-02 2006-04-26 ダイアックス コープ． Generation and selection of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JPH03180192A (en) * 1989-12-07 1991-08-06 Kirin Brewery Co Ltd Production of human pro-tgf-beta1 by genetic recombination
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69130709T3 (en) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. TARGETED IMMUNOSTIMULATION WITH SPECIFIC SUBSTANCES
DE69128253T2 (en) 1990-10-29 1998-06-18 Chiron Corp SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5274166A (en) 1991-01-30 1993-12-28 Ihara Chemical Industry Co., Ltd. Dithiocarbamic acid salt, process for production thereof, and process for production of isothiocyanate using said dithiocarbamic acid salt
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
EP0511011B1 (en) 1991-04-26 1996-10-23 Surface Active Limited Novel antibodies and methods for their use
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3452946B2 (en) 1992-02-19 2003-10-06 協和醗酵工業株式会社 Anti-TGF-β masking protein monoclonal antibody
ATE239506T1 (en) 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2149768T3 (en) 1992-03-25 2000-11-16 Immunogen Inc CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
US5951983A (en) 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DE69432815T2 (en) 1993-03-19 2003-12-11 Univ Johns Hopkins Med GROWTH FACTOR-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
WO1995004069A1 (en) 1993-07-30 1995-02-09 Affymax Technologies N.V. Biotinylation of proteins
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
DK1231268T3 (en) 1994-01-31 2005-11-21 Univ Boston Polyclonal antibody libraries
DE69535976D1 (en) 1994-03-29 2009-08-13 Renovo Ltd Healing of wounds or fibrotic diseases using at least one agent against a growth factor
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5967979A (en) 1995-11-14 1999-10-19 Verg, Inc. Method and apparatus for photogrammetric assessment of biological tissue
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
JP2000507939A (en) 1996-03-22 2000-06-27 ザ ジェネラル ホスピタル コーポレーション Administration of polypeptide growth factor after central nervous system ischemia or trauma
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CA2286879C (en) 1997-04-14 2003-12-16 Peter Kufer Novel method for the production of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
PT2045322E (en) 1997-07-14 2015-10-16 Université de Liège Double-muscling in mammals
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999014353A2 (en) 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
CA2331410C (en) 1998-05-06 2009-07-14 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
EP1117805A2 (en) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
WO2000066620A2 (en) 1999-04-30 2000-11-09 Curis, Inc. Morphogen-induced enhancement of fertility
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6784999B1 (en) 1999-05-17 2004-08-31 The Florida International University Board Of Trustees Surface plasmon resonance detection with high angular resolution and fast response time
TR200200133T2 (en) 1999-07-20 2002-05-21 Pharmexa A/S A method for downstream regulation of GDF-8 activity.
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
IT1317922B1 (en) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe METHOD TO IDENTIFY INTRACELLULAR EPITOPES IN VIVO.
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
DE10108240B4 (en) 2001-02-21 2018-06-28 Leica Microsystems Cms Gmbh Method for imaging and measuring microscopic three-dimensional structures
WO2002067849A2 (en) 2001-02-26 2002-09-06 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
GB0108165D0 (en) 2001-03-31 2001-05-23 Univ Manchester Intracellular analysis
EP1406931A2 (en) 2001-07-19 2004-04-14 Universität Zürich Modification of human variable domains
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
GB0201611D0 (en) 2002-01-24 2002-03-13 Grosveld Frank Transgenic animal
GB0226723D0 (en) 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
ES2537104T3 (en) 2002-05-22 2015-06-02 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin framework regions demonstrating enhanced stability in the intracellular environment and their identification methods
AU2003267246A1 (en) 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
AU2003282247A1 (en) 2002-11-15 2004-06-15 Medical Research Council Anti-activated ras antibodies
EP1482309A1 (en) 2003-05-07 2004-12-01 Institut Curie Means for detecting protein conformation and applications thereof
MXPA05012965A (en) 2003-06-02 2006-03-09 Wyeth Corp Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders.
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
US20050164909A1 (en) * 2003-07-16 2005-07-28 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
US20080206219A1 (en) 2003-08-08 2008-08-28 The Regencts Of The University Of California Novel Indications for Transforming Growth Factor-Beta Regulators
WO2005023870A1 (en) * 2003-09-04 2005-03-17 Riken ANTIBODY RECOGNIZING TGF-β ACTIVATION CONTROLLING REGION SECTION
DK1677735T3 (en) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
KR100500610B1 (en) 2003-10-29 2005-07-11 한국전기연구원 Fluorescent microscope and method for measurement using the same
WO2005063817A2 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
AU2004312411B8 (en) 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
KR20060133049A (en) 2004-03-23 2006-12-22 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
US20100183695A1 (en) 2004-05-27 2010-07-22 John Knopf Cerberus/coco derivatives and uses thereof
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
WO2006031926A2 (en) 2004-09-15 2006-03-23 The Trustees Of The University Of Pennsylvania Methods for the isolation and expansion of cord blood derived t regulatory cells
CN101103045B (en) 2004-09-24 2015-11-25 安姆根有限公司 The Fc molecule modified
WO2006036074A1 (en) 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005323087A1 (en) 2004-12-30 2006-07-13 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
PL3520815T3 (en) 2005-02-08 2022-04-11 Genzyme Corporation Antibodies to tgfbeta
WO2006106599A1 (en) 2005-03-01 2006-10-12 Kyoto University Pharmaceutical for preventing and/or treating disease caused by abnormal enhancement of extracellular domain shedding
US8815526B2 (en) 2005-03-31 2014-08-26 Case Western Reserve University Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals
EP1874818B1 (en) 2005-04-22 2011-04-13 Eli Lilly And Company Tgf beta 1 specific antibodies
JP2008539241A (en) 2005-04-25 2008-11-13 ファイザー インコーポレイティッド Antibody to myostatin
SI2407486T1 (en) 2005-08-19 2018-04-30 Wyeth Llc Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
AU2006302494B2 (en) 2005-10-06 2011-01-06 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP1948675B1 (en) 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
AU2007292555B2 (en) 2006-09-05 2012-05-31 Eli Lilly And Company Anti-myostatin antibodies
JP2008102117A (en) 2006-09-21 2008-05-01 Fujifilm Corp Surface plasmon enhanced fluorescence sensor and fluorescence detecting method
CN104645328A (en) 2006-10-03 2015-05-27 建新公司 Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia
WO2009018438A1 (en) 2007-07-31 2009-02-05 Cornell Research Foundation, Inc. Protein discovery using intracellular ribosome display
KR100988471B1 (en) 2007-07-06 2010-10-18 전자부품연구원 Apparatus for analyzing cell in real-time and method for measuring cellular metabolism using the same
US20100266577A1 (en) 2007-07-25 2010-10-21 Felipe Samaniego Method of Cancer Treatment with Antagonists of FAS Inhibitors
EP2193805A4 (en) 2007-08-24 2013-09-04 Univ Keio Immunosuppression weaning agent comprising tumor cell and antitumor agent using the same
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
WO2009114702A2 (en) 2008-03-14 2009-09-17 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
CA2779472C (en) 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
WO2011102483A1 (en) 2010-02-19 2011-08-25 独立行政法人理化学研究所 HUMAN LAP TGF-β BINDING ANTIBODY
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
AR081556A1 (en) 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
KR20140005864A (en) 2010-08-16 2014-01-15 암젠 인코퍼레이티드 Antibodies that bind myostatin, compositions and methods
NZ610267A (en) 2010-10-08 2015-05-29 Hope City A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
JP5963746B2 (en) 2011-03-30 2016-08-03 国立大学法人富山大学 Plasma cell or plasmablast selection method, target antigen-specific antibody production method, novel monoclonal antibody
EP3954704A1 (en) * 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
US9505763B2 (en) 2011-07-25 2016-11-29 Vanderbilt University Cancer treatment using BMP inhibitor
CN103890246A (en) 2011-08-18 2014-06-25 亲和生物科学公司 Soluble polypeptides
US10071129B2 (en) 2011-08-30 2018-09-11 Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. Method for identifying bromodomain inhibitors
JP6076357B2 (en) 2011-10-10 2017-02-08 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Meditope and meditope-binding antibodies and uses thereof
ES2663946T3 (en) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Compositions and methods to increase muscle mass and strength by specifically antagonizing GDF8 and / or Activin A
SI2794658T1 (en) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecific antibody molecule
CN104487453B (en) 2012-06-15 2018-09-28 辉瑞公司 The antagonist antibodies and application thereof of improved anti-GDF-8
CN113234142B (en) 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 Screening and reconstruction method of hyperstable immunoglobulin variable domain and application thereof
IL270110B (en) 2012-09-13 2022-08-01 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
JP6480907B2 (en) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター Multimerization technology
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
CA2947967A1 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2015342936B2 (en) * 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof

Also Published As

Publication number Publication date
US9399676B2 (en) 2016-07-26
US20160289318A1 (en) 2016-10-06
US20210284722A1 (en) 2021-09-16
US20200131259A1 (en) 2020-04-30
US20160031980A1 (en) 2016-02-04
JP2016521283A (en) 2016-07-21
EP3816625A1 (en) 2021-05-05
EP2981822B1 (en) 2020-09-02
IL281549B2 (en) 2023-08-01
AU2021204415A1 (en) 2021-07-29
US10981981B2 (en) 2021-04-20
JP2017200915A (en) 2017-11-09
WO2014182676A3 (en) 2015-02-05
US11827698B2 (en) 2023-11-28
PT2981822T (en) 2020-12-07
US9758577B2 (en) 2017-09-12
IL242193B (en) 2021-04-29
ES2837042T3 (en) 2021-06-29
JP2021050201A (en) 2021-04-01
CY1123907T1 (en) 2022-03-24
PL2981822T3 (en) 2021-07-12
SG10201913751RA (en) 2020-03-30
LT2981822T (en) 2020-12-28
US20180022798A1 (en) 2018-01-25
AU2017203611B2 (en) 2019-03-07
DK2981822T3 (en) 2020-12-07
US20190085067A1 (en) 2019-03-21
US9580500B2 (en) 2017-02-28
US9758576B2 (en) 2017-09-12
HRP20201914T1 (en) 2021-01-22
AU2014262843B2 (en) 2017-06-22
AU2014262843A1 (en) 2015-11-19
IL301607A (en) 2023-05-01
RS61778B1 (en) 2021-06-30
IL281549A (en) 2021-05-31
HUE052232T2 (en) 2021-04-28
AU2017203611A1 (en) 2017-06-15
US20150337034A1 (en) 2015-11-26
US20170210798A1 (en) 2017-07-27
WO2014182676A2 (en) 2014-11-13
EP2981822A4 (en) 2017-02-15
PL2981822T4 (en) 2021-07-12
US20180016332A1 (en) 2018-01-18
JP2023156328A (en) 2023-10-24
US20150361421A1 (en) 2015-12-17
IL281549B1 (en) 2023-04-01
AU2019203834A1 (en) 2019-06-20
US20150361175A1 (en) 2015-12-17
CA2911514A1 (en) 2014-11-13
SI2981822T1 (en) 2021-08-31
JP6796695B2 (en) 2020-12-09
SG10201800800YA (en) 2018-03-28
AU2017203611C1 (en) 2021-12-23
US9573995B2 (en) 2017-02-21
US20170190767A1 (en) 2017-07-06
EP2981822A2 (en) 2016-02-10
US10597443B2 (en) 2020-03-24
JP2020062007A (en) 2020-04-23

Similar Documents

Publication Publication Date Title
IL281549A (en) Compositions and methods for growth factor modulation
IL289821A (en) Compositions and methods for immunotherapy
HK1220387A1 (en) Compositions and methods for immunotherapy
IL244081A0 (en) Compositions and methods for modulating rna
ZA201506710B (en) Compositions and methods for enhancing plant growth
PT3524680T (en) Compositions and methods for modulating ttr expression
EP2978300A4 (en) Compositions and methods for enhancing microbial stability
HK1218659A1 (en) Compositions and methods for modulating tau expression tau
IL285527A (en) Compositions and methods for immunotherapy
ZA201602073B (en) Compositions and methods for improving plant growth
EP2744490A4 (en) Methods and compositions for increasing growth hormones